ASF1A and lung adenocarcinoma: In lung adenocarcinomas, ASF1A deficiency could sensitize lung adenocarcinomas to anti-PD-1 therapy by inducing immunogenic M1-like macrophage differentiation and enhancing T cell activation of the TME [26].